Wells Fargo upgraded Caredx Inc (NASDAQ:CDNA) to "Equal Weight" from "Underweight" given a more balanced risk/reward profile after a roughly 30% decline in the stock since late August, contrasting ...

Wells Fargo has upgraded CareDx (NASDAQ:CDNA) to equal weight from underweight, citing valuation, but lowered its price ...

In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on CareDx (CDNA – Research Report), with a price target of ...

(RTTNews) - CareDx, Inc. (CDNA), Monday reported preliminary loss for the fourth quarter and a 30 percent increase preliminary revenues. For the quarter, the company projects loss to be approximately ...

CareDx (NASDAQ:CDNA) expects to incur a loss (GAAP) of around $32M to $34M for the fourth quarter of 2024, on revenue of $85M ...

The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.

Natera Inc. failed to convince a federal judge to rule CareDx Inc.'s DNA-based tests infringe a second patent for detecting organ-transplant rejections or that it deserves a new trial on the issue, ...

NEW YORK – After two years of decline in 2022 and 2023, the 360Dx Top 30 rebounded in 2024, rising 4 percent year over year.

CareDx faces regulatory challenges and lacks a durable competitive advantage in a fragmented and competitive market, with no clear moat to protect its position, leading to a poor risk-reward profile.